Publication:

Isotype-Specific Inhibition of the Phosphatidylinositol-3-Kinase Pathway in Hematologic Malignancies

Thumbnail Image

Open/View Files

Primary ott-7-333.pdf (614.37 KB)

Date

2014-02-21

Authors

Published Version

10.2147/ott.s34641

Journal Title

Journal ISSN

Volume Title

Publisher

Informa UK Limited
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Castillo, Jorge, Meera Iyengar, Benjamin Kuritzky, Kenneth Bishop. "Isotype-Specific Inhibition of the Phosphatidylinositol-3-Kinase Pathway in Hematologic Malignancies." OncoTargets and Therapy 7 (2014): 333-342. DOI: 10.2147/ott.s34641

Abstract

In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an important role in the pathogenesis and survival advantage in hematologic malignancies, such as leukemia, lymphoma, and myeloma. The objectives of the present review, hence, are to describe the current knowledge on the PI3K pathway and its isoforms, and to summarize preclinical and clinical studies using PI3K inhibitors, focusing on the advances made in hematologic malignancies.

Description

Other Available Sources

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937185/

Research Data

Keywords

Research Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological research::Pharmacology, Research Subject Categories::MEDICINE::Surgery::Oncology

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

URI

https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37369267

Collections

HMS Scholarly Articles

Endorsement

Review

Supplemented By

Related Stories